framycetin has been researched along with Hyperlipoproteinemia Type III in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gotto, AM; Jones, PH; Scott, LW | 1 |
| Parker, F | 1 |
1 review(s) available for framycetin and Hyperlipoproteinemia Type III
| Article | Year |
|---|---|
The diagnosis and management of hyperlipidemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Cholestyramine Resin; Chylomicrons; Clofibrate; Colestipol; Coronary Disease; Dextrothyroxine; Dietary Fats; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hyperlipoproteinemia Type I; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hyperlipoproteinemia Type IV; Hyperlipoproteinemia Type V; Lipoproteins; Lipoproteins, LDL; Neomycin; Niacin; Pentanoic Acids; Probucol; Receptors, LDL; Triglycerides | 1986 |
1 other study(ies) available for framycetin and Hyperlipoproteinemia Type III
| Article | Year |
|---|---|
Xanthomas and hyperlipidemias.
Topics: Apoproteins; Arteriosclerosis; Cholestasis; Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyroxine; Diabetes Complications; Female; Humans; Hyperlipidemias; Hyperlipoproteinemia Type III; Hyperlipoproteinemia Type IV; Hyperlipoproteinemias; Hypolipidemic Agents; Hypothyroidism; Kidney Diseases; Lipoproteins; Male; Neomycin; Niacin; Obesity; Pancreatitis; Xanthomatosis | 1985 |